JP2005513419A - 続発性上皮小体機能亢進症を有する腎性患者における上皮小体ホルモンの治療的抑制をモニタリングおよび誘導するための方法 - Google Patents
続発性上皮小体機能亢進症を有する腎性患者における上皮小体ホルモンの治療的抑制をモニタリングおよび誘導するための方法 Download PDFInfo
- Publication number
- JP2005513419A JP2005513419A JP2003541863A JP2003541863A JP2005513419A JP 2005513419 A JP2005513419 A JP 2005513419A JP 2003541863 A JP2003541863 A JP 2003541863A JP 2003541863 A JP2003541863 A JP 2003541863A JP 2005513419 A JP2005513419 A JP 2005513419A
- Authority
- JP
- Japan
- Prior art keywords
- pth
- level
- agonist
- patient
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000445 Parathyroid hormone Proteins 0.000 title claims abstract description 476
- 102000003982 Parathyroid hormone Human genes 0.000 title claims abstract description 475
- 239000000199 parathyroid hormone Substances 0.000 title claims abstract description 474
- 229960001319 parathyroid hormone Drugs 0.000 title claims abstract description 474
- 238000000034 method Methods 0.000 title claims abstract description 59
- 238000012544 monitoring process Methods 0.000 title claims abstract description 33
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 18
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 title claims abstract description 17
- 230000001629 suppression Effects 0.000 title claims abstract description 15
- 230000001939 inductive effect Effects 0.000 title claims abstract description 7
- 239000000556 agonist Substances 0.000 claims abstract description 137
- 239000005557 antagonist Substances 0.000 claims abstract description 131
- 201000002980 Hyperparathyroidism Diseases 0.000 claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 32
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 22
- 239000011575 calcium Substances 0.000 claims description 22
- 229910052791 calcium Inorganic materials 0.000 claims description 22
- 229930003316 Vitamin D Natural products 0.000 claims description 21
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 21
- 235000019166 vitamin D Nutrition 0.000 claims description 21
- 239000011710 vitamin D Substances 0.000 claims description 21
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 21
- 229940046008 vitamin d Drugs 0.000 claims description 21
- 229940124597 therapeutic agent Drugs 0.000 claims description 20
- 238000007470 bone biopsy Methods 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 208000020832 chronic kidney disease Diseases 0.000 claims description 11
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims description 10
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims description 10
- 102000058004 human PTH Human genes 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 9
- 208000005475 Vascular calcification Diseases 0.000 claims description 9
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 235000020964 calcitriol Nutrition 0.000 claims description 8
- 239000011612 calcitriol Substances 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 6
- DTXXSJZBSTYZKE-ZDQKKZTESA-N Maxacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](OCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C DTXXSJZBSTYZKE-ZDQKKZTESA-N 0.000 claims description 6
- 229960005084 calcitriol Drugs 0.000 claims description 6
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 6
- 238000003018 immunoassay Methods 0.000 claims description 6
- 229950006319 maxacalcitol Drugs 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 5
- 229960002061 ergocalciferol Drugs 0.000 claims description 5
- 235000001892 vitamin D2 Nutrition 0.000 claims description 5
- 239000011653 vitamin D2 Substances 0.000 claims description 5
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims description 4
- 229960002535 alfacalcidol Drugs 0.000 claims description 4
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 4
- -1 calciferdiol Chemical compound 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 230000008416 bone turnover Effects 0.000 description 20
- 239000003112 inhibitor Substances 0.000 description 19
- 239000012634 fragment Substances 0.000 description 18
- 201000010099 disease Diseases 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 210000000988 bone and bone Anatomy 0.000 description 12
- 238000005259 measurement Methods 0.000 description 8
- 230000000849 parathyroid Effects 0.000 description 8
- 201000000523 end stage renal failure Diseases 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000028208 end stage renal disease Diseases 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 208000004434 Calcinosis Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000002308 calcification Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 3
- BPKAHTKRCLCHEA-FOPGHSPUSA-N 19-Nor-1-α,25-dihydroxyvitamin D2 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](C=C[C@H](C)C(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-FOPGHSPUSA-N 0.000 description 3
- 101710095468 Cyclase Proteins 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 3
- 229960003315 cinacalcet Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 229940052212 zemplar Drugs 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020707 Hyperparathyroidism primary Diseases 0.000 description 2
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 208000005368 osteomalacia Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000016216 Choristoma Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 206010050977 Hypocalciuria Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 1
- 229960004361 calcifediol Drugs 0.000 description 1
- 229940097712 calcijex Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000036540 impulse transmission Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 208000027361 mineral metabolism disease Diseases 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 108010066022 parathyroid hormone (7-84) Proteins 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000006078 pseudohypoparathyroidism Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010038433 renal dysplasia Diseases 0.000 description 1
- 229940106904 rocaltrol Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000002037 soft tissue calcification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 102000009310 vitamin D receptors Human genes 0.000 description 1
- 108050000156 vitamin D receptors Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/046—Thyroid disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/002,818 US6524788B1 (en) | 2001-11-02 | 2001-11-02 | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| US10/286,465 US7056655B2 (en) | 2001-11-02 | 2002-11-01 | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| PCT/US2002/035516 WO2003039572A1 (en) | 2001-11-02 | 2002-11-04 | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005513419A true JP2005513419A (ja) | 2005-05-12 |
| JP2005513419A5 JP2005513419A5 (enExample) | 2006-01-12 |
Family
ID=26670921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003541863A Pending JP2005513419A (ja) | 2001-11-02 | 2002-11-04 | 続発性上皮小体機能亢進症を有する腎性患者における上皮小体ホルモンの治療的抑制をモニタリングおよび誘導するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7056655B2 (enExample) |
| EP (1) | EP1448217A4 (enExample) |
| JP (1) | JP2005513419A (enExample) |
| CA (1) | CA2465862A1 (enExample) |
| WO (1) | WO2003039572A1 (enExample) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009541348A (ja) * | 2006-06-21 | 2009-11-26 | プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー | 二次性副甲状腺機能亢進症の治療及び予防方法 |
| JP2010525080A (ja) * | 2007-04-25 | 2010-07-22 | プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー | 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法 |
| US9408858B2 (en) | 2007-04-25 | 2016-08-09 | Opko Renal, Llc | Method for treating secondary hyperparathyroidism in CKD |
| US9861644B2 (en) | 2013-03-15 | 2018-01-09 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US9943530B2 (en) | 2006-02-03 | 2018-04-17 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US10302660B2 (en) | 2008-04-02 | 2019-05-28 | Opko Renal, Llc | Methods useful for vitamin D deficiency and related disorders |
| US11173168B2 (en) | 2016-03-28 | 2021-11-16 | Eirgen Pharma Ltd. | Methods of treating vitamin D insufficiency in chronic kidney disease |
| US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820393B2 (en) * | 1999-01-14 | 2010-10-26 | Scantibodies Laboratory, Inc. | Methods, kits and antibodies for detecting parathyroid hormone |
| US6689566B1 (en) | 1999-01-14 | 2004-02-10 | Scantibodies Laboratory, Inc. | Methods, kits, and antibodies for detecting parathyroid hormone |
| US6838264B2 (en) * | 2000-12-05 | 2005-01-04 | Immutopics, Inc. | Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84 |
| EP1945185B1 (en) * | 2005-10-12 | 2016-02-03 | Proventiv Therapeutics, LLC | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency |
| CA2684778C (en) | 2007-04-25 | 2017-09-05 | Cytochroma Inc. | Methods and compounds for vitamin d therapy |
| CN108445237A (zh) * | 2018-06-20 | 2018-08-24 | 广州市康润生物科技有限公司 | 一种pth快速免疫检测系统的新用途 |
| CN112349362B (zh) * | 2019-08-08 | 2025-06-20 | 深圳先进技术研究院 | 一种甲状旁腺激素分泌监测与调控系统 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369138A (en) * | 1980-07-15 | 1983-01-18 | Immuno Nuclear Corporation | Parathyroid radioimmunoassay |
| US4423037A (en) * | 1982-05-13 | 1983-12-27 | The General Hospital Corporation | Inhibitors of peptide hormone action |
| US4508828A (en) * | 1983-03-21 | 1985-04-02 | Immuno Nuclear Corporation | Bioassay of parathyroid hormone |
| FR2550204B1 (fr) * | 1983-08-05 | 1987-11-13 | Toyo Jozo Kk | Derives peptidiques de (nle8,nle1b, tyr34)-h-pth |
| DE3347548A1 (de) | 1983-12-30 | 1985-07-11 | Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch | Mittel und verfahren zur spezifischen immunologischen bestimmung des c-terminalen parathormonfragments 68-84 |
| DE3935738A1 (de) | 1989-10-27 | 1991-05-08 | Forssmann Wolf Georg | Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff |
| US5317010A (en) | 1991-10-10 | 1994-05-31 | Peter K. T. Pang | Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment |
| WO1994003201A1 (en) | 1992-08-05 | 1994-02-17 | Hilliker Sandra R | Parathyroid hormone fragments and analogs |
| DE4434551A1 (de) | 1994-09-28 | 1996-04-04 | Forssmann Wolf Georg Prof Dr D | Peptide aus der Sequenz des hPTH (1-37) |
| US6689566B1 (en) * | 1999-01-14 | 2004-02-10 | Scantibodies Laboratory, Inc. | Methods, kits, and antibodies for detecting parathyroid hormone |
| US6923968B2 (en) * | 2000-08-10 | 2005-08-02 | Scantibodies Laboratory, Inc. | Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis |
| US6524788B1 (en) * | 2001-11-02 | 2003-02-25 | Thomas L. Cantor | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
-
2002
- 2002-11-01 US US10/286,465 patent/US7056655B2/en not_active Expired - Fee Related
- 2002-11-04 EP EP02776462A patent/EP1448217A4/en not_active Withdrawn
- 2002-11-04 JP JP2003541863A patent/JP2005513419A/ja active Pending
- 2002-11-04 CA CA002465862A patent/CA2465862A1/en not_active Abandoned
- 2002-11-04 WO PCT/US2002/035516 patent/WO2003039572A1/en not_active Ceased
-
2006
- 2006-03-17 US US11/377,980 patent/US20060223119A1/en not_active Abandoned
Cited By (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9943530B2 (en) | 2006-02-03 | 2018-04-17 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| US10213442B2 (en) | 2006-02-03 | 2019-02-26 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| US11007204B2 (en) | 2006-02-03 | 2021-05-18 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| US11911398B2 (en) | 2006-02-03 | 2024-02-27 | Opko Renal, Llc | Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| US10668089B2 (en) | 2006-06-21 | 2020-06-02 | Opko Ireland Global Holdings, Ltd. | Method of treating and preventing secondary hyperparathyroidism |
| JP2009541348A (ja) * | 2006-06-21 | 2009-11-26 | プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー | 二次性副甲状腺機能亢進症の治療及び予防方法 |
| US9498486B1 (en) | 2007-04-25 | 2016-11-22 | Opko Renal, Llc | Method for controlled release oral dosage of a vitamin D compound |
| US9925147B2 (en) | 2007-04-25 | 2018-03-27 | Opko Renal, Llc | Method for treating secondary hyperparathyroidism in CKD |
| US9918940B2 (en) | 2007-04-25 | 2018-03-20 | Opko Renal, Llc | Methods for controlled release oral dosage of a vitamin D compound |
| US9408858B2 (en) | 2007-04-25 | 2016-08-09 | Opko Renal, Llc | Method for treating secondary hyperparathyroidism in CKD |
| US11801253B2 (en) | 2007-04-25 | 2023-10-31 | Opko Renal, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
| JP2014098034A (ja) * | 2007-04-25 | 2014-05-29 | Proventiv Therapeutics Llc | 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法 |
| JP2019196402A (ja) * | 2007-04-25 | 2019-11-14 | オプコ リーナル リミテッド ライアビリティ カンパニー | 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法 |
| US11154509B2 (en) | 2007-04-25 | 2021-10-26 | Eirgen Pharma Ltd. | Methods for controlled release oral dosage of a vitamin D compound |
| JP2010525080A (ja) * | 2007-04-25 | 2010-07-22 | プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー | 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法 |
| US10302660B2 (en) | 2008-04-02 | 2019-05-28 | Opko Renal, Llc | Methods useful for vitamin D deficiency and related disorders |
| US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| US10357502B2 (en) | 2013-03-15 | 2019-07-23 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US11253528B2 (en) | 2013-03-15 | 2022-02-22 | Eirgen Pharma Ltd. | Stabilized modified release Vitamin D formulation and method of administering same |
| US10350224B2 (en) | 2013-03-15 | 2019-07-16 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US10300078B2 (en) | 2013-03-15 | 2019-05-28 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US9861644B2 (en) | 2013-03-15 | 2018-01-09 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US12478631B2 (en) | 2013-03-15 | 2025-11-25 | Eirgen Pharma Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US11007205B2 (en) | 2014-08-07 | 2021-05-18 | Eirgen Pharma Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US10493084B2 (en) | 2014-08-07 | 2019-12-03 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US11738033B2 (en) | 2014-08-07 | 2023-08-29 | Eirgen Pharma Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US11173168B2 (en) | 2016-03-28 | 2021-11-16 | Eirgen Pharma Ltd. | Methods of treating vitamin D insufficiency in chronic kidney disease |
| US12208106B2 (en) | 2016-03-28 | 2025-01-28 | Eirgen Pharma Ltd. | Methods of vitamin D treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1448217A1 (en) | 2004-08-25 |
| US20060223119A1 (en) | 2006-10-05 |
| CA2465862A1 (en) | 2003-05-15 |
| EP1448217A4 (en) | 2008-05-14 |
| US20030157560A1 (en) | 2003-08-21 |
| WO2003039572A1 (en) | 2003-05-15 |
| US7056655B2 (en) | 2006-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005513419A (ja) | 続発性上皮小体機能亢進症を有する腎性患者における上皮小体ホルモンの治療的抑制をモニタリングおよび誘導するための方法 | |
| JP4231106B2 (ja) | 骨溶解および転移を改善する方法 | |
| US8298770B2 (en) | Methods, kits, and antibodies for detecting parathyroid hormone | |
| EP1151307B1 (en) | Methods for differentiating and monitoring parathyroid and bone status related diseases | |
| Sano et al. | Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis. | |
| US20240279323A1 (en) | Methods for the treatment of scleroderma and related conditions | |
| US6524788B1 (en) | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism | |
| Hong et al. | Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women | |
| Emerson et al. | Recombinant human thyroid-stimulating hormone: pharmacology, clinical applications and potential uses | |
| TWI746505B (zh) | 通過測量血漿生物標記的水平預測疑似患有癌症的患者使用阿柏西普的治療的結果的方法 | |
| Mitlak et al. | Parathyroid hormone-related peptide mediates hypercalcemia in an islet cell tumor of the pancreas | |
| CN111050786A (zh) | 用于治疗非酒精性脂肪性肝炎(nash)的方法的修饰的成纤维细胞生长因子21(fgf-21) | |
| Buzi et al. | Antigenicity and efficacy of authentic sequence recombinant human growth hormone (somatropin): first‐year experience in the United Kingdom | |
| CN115867577A (zh) | 用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物 | |
| US7541140B2 (en) | Assessing risk for kidney stones using parathyroid hormone agonist and antagonist | |
| US7465703B1 (en) | Methods and kits useful for guiding osteoporosis related therapy | |
| Janeway et al. | A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group | |
| AU2018263159A1 (en) | Methods of selectively treating asthma using IL-17 antagonists | |
| HUP0100105A2 (hu) | TNF-antagonisták alkalmazása szeptikus betegségek kezelésére szolgáló gyógyszerként | |
| Reddi | Disorders of Calcium: Hypercalcemia | |
| Holt et al. | Physiology and pathophysiology of the parathyroid glands and preoperative evaluation | |
| Elmaaz et al. | A Case of Acute Pancreatitis as a First Presentation of Primary Hyperparathyroidism | |
| US20100021496A1 (en) | Methods, kits, and antibodies for quantitative determination of parathyroid hormone molecules with intact c-terminus | |
| Gallacher | Use of currently available diagnostic and therapeutic tools in the investigation and treatment of disorders of bone and calcium metabolism | |
| Lekamwasam | 6. Miscellaneous bone disorders among older adults |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050719 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050719 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081106 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090417 |